医药科技服务

Search documents
普蕊斯股价涨5.15%,融通基金旗下1只基金位居十大流通股东,持有100万股浮盈赚取236万元
Xin Lang Cai Jing· 2025-09-30 03:32
Group 1 - The core viewpoint of the news is that Prasis (Shanghai) Pharmaceutical Technology Development Co., Ltd. has seen a stock price increase of 5.15%, reaching 48.16 CNY per share, with a total market capitalization of 3.805 billion CNY as of September 30 [1] - The company was established on February 22, 2013, and went public on May 17, 2022, focusing on technology development, transfer, consulting, and services in the pharmaceutical sector, with 100% of its revenue coming from services [1] - The trading volume for Prasis on the reporting date was 75.4268 million CNY, with a turnover rate of 2.13% [1] Group 2 - Among the top ten circulating shareholders of Prasis, a fund under Rongtong Fund has increased its holdings by 100,000 shares to a total of 1 million shares, representing 1.33% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) has achieved a year-to-date return of 17.3% and a one-year return of 23.7%, ranking 4996 out of 8167 and 4660 out of 8010 in its category, respectively [2] - The fund was established on December 25, 2014, and has a current size of 2.074 billion CNY, with a cumulative return of 183.4% since inception [2]
诺思格股价跌5.08%,东财基金旗下1只基金重仓,持有1.24万股浮亏损失3.48万元
Xin Lang Cai Jing· 2025-09-23 05:52
9月23日,诺思格跌5.08%,截至发稿,报52.52元/股,成交8287.77万元,换手率2.69%,总市值50.72亿 元。诺思格股价已经连续4天下跌,区间累计跌幅4.6%。 资料显示,诺思格(北京)医药科技股份有限公司位于北京市海淀区车公庄西路19号华通大厦B座北塔11 层,成立日期2008年8月22日,上市日期2022年8月2日,公司主营业务涉及临床试验运营服务、临床试 验现场管理服务、生物样本检测服务、数据管理与统计分析服务、临床试验咨询服务、临床药理学服务 等。主营业务收入构成为:临床试验运营服务39.25%,临床试验现场管理服务34.10%,数据管理与统 计分析服务13.30%,生物样本检测服务8.45%,临床药理学服务3.74%,临床试验咨询服务1.16%。 从基金十大重仓股角度 数据显示,东财基金旗下1只基金重仓诺思格。东财远见成长混合发起式A(018088)二季度持有股数 1.24万股,占基金净值比例为4.85%,位居第五大重仓股。根据测算,今日浮亏损失约3.48万元。连续4 天下跌期间浮亏损失3.31万元。 东财远见成长混合发起式A(018088)成立日期2023年4月11日,最新规模9 ...
诺思格: 第五届董事会第十三次会议决议公告
Zheng Quan Zhi Xing· 2025-09-05 16:22
整,没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码:301333 证券简称:诺思格 公告编号:2025-038 诺思格(北京)医药科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确、完 诺思格(北京)医药科技股份有限公司(以下简称"公司")第五届董事会 第十三次会议(以下简称"本次会议")于2025年9月5日在公司会议室以现场结 合通讯方式召开。会议通知已于2025年8月29日以电子邮件及专人送达等方式送 达全体董事。本次会议应出席董事9人,实际出席董事9人。会议由董事长WU JIE (武杰)先生主持,会议的召开符合有关法律、法规、规章和《诺思格(北京) 医药科技股份有限公司章程》(以下简称《公司章程》)的规定。 二、董事会会议审议情况 (一)审议通过《关于 <公司2025年员工持股计划 草案="草案"> 及其摘要的议 案》 表决情况:9票同意;0票弃权;0票反对。 为建立和完善员工、股东的利益共享机制,改善公司治理水平,提高核心团 队的凝聚力和公司竞争力,调动员工的积极性和创造性,促进公司长期、持续、 健康发展,公司依据《中华人民共和国公司法》 (以下简称" 《公司 ...
诺思格8月29日获融资买入1592.23万元,融资余额8492.47万元
Xin Lang Zheng Quan· 2025-09-01 02:18
Core Insights - On August 29, Norscare's stock rose by 2.93% with a trading volume of 166 million yuan [1] - The company reported a financing buy-in of 15.92 million yuan and a financing repayment of 17.69 million yuan, resulting in a net financing outflow of 1.77 million yuan [1] - As of August 29, the total financing and securities lending balance for Norscare was 84.92 million yuan, which is 2.80% of its market capitalization, indicating a high level of financing balance compared to the past year [1] Company Overview - Norscare (Beijing) Pharmaceutical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022 [2] - The company specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2] - The revenue composition includes: clinical trial operation services (43.01%), clinical trial site management services (27.52%), data management and statistical analysis services (13.53%), biological sample testing services (8.54%), clinical pharmacology services (4.33%), and clinical trial consulting services (3.08%) [2] Financial Performance - For the first half of 2025, Norscare achieved a revenue of 380 million yuan, representing a year-on-year growth of 0.18% [2] - The net profit attributable to the parent company was 61.12 million yuan, reflecting a year-on-year increase of 4.45% [2] - Cumulative cash dividends since the A-share listing amount to 49.50 million yuan [3] Shareholder Structure - As of June 30, 2025, the number of shareholders for Norscare was 10,400, an increase of 2.06% from the previous period [2] - The average number of circulating shares per shareholder was 5,486, a decrease of 1.97% from the previous period [2] - New institutional shareholders include Hong Kong Central Clearing Limited and two funds from Zhonggeng, which entered the top ten circulating shareholders [3]
诺思格8月28日获融资买入1942.17万元,融资余额8669.17万元
Xin Lang Cai Jing· 2025-08-29 02:05
Core Viewpoint - The company Norse Group (Beijing) Pharmaceutical Technology Co., Ltd. has shown stable financial performance with slight growth in revenue and net profit, while also experiencing significant trading activity in its stock. Group 1: Financial Performance - For the period from January to June 2025, Norse Group achieved operating revenue of 380 million yuan, representing a year-on-year growth of 0.18% [2] - The net profit attributable to the parent company was 61.12 million yuan, reflecting a year-on-year increase of 4.45% [2] - Cumulative cash dividends since the company's A-share listing amounted to 49.50 million yuan [3] Group 2: Business Operations - The company's main business segments include clinical trial operation services (43.01%), clinical trial site management services (27.52%), data management and statistical analysis services (13.53%), biological sample testing services (8.54%), clinical pharmacology services (4.33%), and clinical trial consulting services (3.08%) [2] - As of June 30, 2025, the number of shareholders increased to 10,400, up by 2.06% from the previous period, while the average circulating shares per person decreased by 1.97% to 5,486 shares [2] Group 3: Stock Trading Activity - On August 28, Norse Group's stock price fell by 0.39%, with a trading volume of 149 million yuan [1] - The financing buy-in amount for Norse Group on the same day was 19.42 million yuan, with a net buy of 5.95 million yuan after 13.47 million yuan in financing repayments [1] - The total financing and securities lending balance reached 86.69 million yuan, accounting for 2.94% of the circulating market value, indicating a high level compared to the past year [1]
普蕊斯: 华泰联合证券有限责任公司关于普蕊斯(上海)医药科技开发股份有限公司持续督导期2025年培训情况报告
Zheng Quan Zhi Xing· 2025-08-26 08:11
Group 1 - The core viewpoint of the report is that Huatai United Securities has conducted a comprehensive training program for the management of Pursis (Shanghai) Pharmaceutical Technology Development Co., Ltd. to ensure compliance with regulatory requirements and enhance corporate governance [1][2] - The training covered key topics such as the use and management of raised funds, transaction norms, corporate governance, internal control, and significant financial risks, emphasizing the importance of compliance and ethical behavior for listed companies and their stakeholders [1][2] - The training aimed to strengthen the legal awareness and integrity of the participants, enhancing their understanding of the responsibilities and obligations of management in corporate governance and compliance [1][2] Group 2 - The training team consisted of experienced professionals with expertise in securities, law, and finance, ensuring a thorough and systematic approach to the training [2] - The training resulted in improved understanding of relevant laws, regulations, and business rules among Pursis's board members, supervisors, and senior management, contributing to better corporate governance [2] - The overall effectiveness of the training is expected to further elevate Pursis's governance standards and operational compliance [2]
诺思格: 中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司终止部分募投项目并将剩余募集资金永久补充流动资金的核查意见
Zheng Quan Zhi Xing· 2025-06-05 09:37
Core Viewpoint - The company has decided to terminate the "Data Science Center Project" and permanently supplement the remaining raised funds into working capital due to changes in market conditions and its operational strategy [4][6][8]. Fundraising Overview - The company raised a total of RMB 1,183.2 million from its initial public offering, with a net amount of RMB 1,087.6 million after deducting issuance costs [1]. - As of April 30, 2025, the company has used RMB 578.5 million of the raised funds, leaving a balance of RMB 558.9 million [2]. Investment Project Status - The total investment for committed projects is RMB 610 million, with RMB 298.5 million already invested [2]. - The company has also allocated RMB 477.6 million for projects funded by excess raised funds, with RMB 280 million already utilized [2]. Termination of Investment Projects - The "Data Science Center Project" was intended to enhance the company's data management and statistical analysis capabilities but has been terminated due to macroeconomic factors and market demand changes [5][6]. - The remaining funds from this project, amounting to RMB 177.7 million, will be permanently added to working capital [6]. Impact on Daily Operations - The termination of the project is expected to have no adverse effects on the company's existing operations and is seen as a strategic decision to optimize fund usage [6][8]. - The decision aligns with the company's goal to improve the efficiency of fund utilization and meet daily operational funding needs [6][8]. Approval Process - The board of directors has approved the termination of the project and the reallocation of funds, which will be submitted for shareholder approval [7][8]. Sponsor's Review Opinion - The sponsor believes that the decision to terminate the project and reallocate funds is in line with the company's operational needs and will enhance the economic benefits of the raised funds [8][9].
诺思格: 第四届监事会第八次会议决议公告
Zheng Quan Zhi Xing· 2025-06-05 09:15
Group 1 - The company held its fourth supervisory board meeting on June 5, 2025, with all three supervisors present, complying with legal and regulatory requirements [1][2] - The supervisory board approved the proposal to terminate the data science center project and permanently allocate the remaining raised funds to supplement working capital, with a unanimous vote of 3 in favor [1][2] - The decision to terminate the project was made based on the company's actual situation and long-term development plan, aiming to improve the efficiency of fund utilization and align with the interests of the company and its shareholders [2]